Search

Your search keyword '"Klaus Koopmans"' showing total 2 results
Start Over Author "Klaus Koopmans"
2 results on '"Klaus Koopmans"'

1. A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management

Author

Kjell Oberg, Eric Krenning, Anders Sundin, Lisa Bodei, Mark Kidd, Margot Tesselaar, Valentina Ambrosini, Richard P Baum, Matthew Kulke, Marianne Pavel, Jaroslaw Cwikla, Ignat Drozdov, Massimo Falconi, Nicola Fazio, Andrea Frilling, Robert Jensen, Klaus Koopmans, Tiny Korse, Dik Kwekkeboom, Helmut Maecke, Giovanni Paganelli, Ramon Salazar, Stefano Severi, Jonathan Strosberg, Vikas Prasad, Aldo Scarpa, Ashley Grossman, Annemeik Walenkamp, Mauro Cives, Irene Virgolini, Andreas Kjaer, and Irvin M Modlin

Subjects
imaging, mRNA, MRI, multianalyte, NETest, neuroendocrine tumor, PET, RECIST, somatostatin, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Abstract

The complexity of the clinical management of neuroendocrine neoplasia (NEN) is exacerbated by limitations in imaging modalities and a paucity of clinically useful biomarkers. Limitations in currently available imaging modalities reflect difficulties in measuring an intrinsically indolent disease, resolution inadequacies and inter-/intra-facility device variability and that RECIST (Response Evaluation Criteria in Solid Tumors) criteria are not optimal for NEN. Limitations of currently used biomarkers are that they are secretory biomarkers (chromogranin A, serotonin, neuron-specific enolase and pancreastatin); monoanalyte measurements; and lack sensitivity, specificity and predictive capacity. None of them meet the NIH metrics for clinical usage. A multinational, multidisciplinary Delphi consensus meeting of NEN experts (n = 33) assessed current imaging strategies and biomarkers in NEN management. Consensus (>75%) was achieved for 78% of the 142 questions. The panel concluded that morphological imaging has a diagnostic value. However, both imaging and current single-analyte biomarkers exhibit substantial limitations in measuring the disease status and predicting the therapeutic efficacy. RECIST remains suboptimal as a metric. A critical unmet need is the development of a clinico-biological tool to provide enhanced information regarding precise disease status and treatment response. The group considered that circulating RNA was better than current general NEN biomarkers and preliminary clinical data were considered promising. It was resolved that circulating multianalyte mRNA (NETest) had clinical utility in both diagnosis and monitoring disease status and therapeutic efficacy. Overall, it was concluded that a combination of tumor spatial and functional imaging with circulating transcripts (mRNA) would represent the future strategy for real-time monitoring of disease progress and therapeutic efficacy.

Published
2016
Full Text
View/download PDF

2. A Delphic consensus assessment : imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management

Author

Eric P. Krenning, Ashley B. Grossman, Giovanni Paganelli, Nicola Fazio, Mauro Cives, Annemeik Walenkamp, Anders Sundin, Jonathan R. Strosberg, Klaus Koopmans, Irene Virgolini, Mark Kidd, Lisa Bodei, Andreas Kjaer, Stefano Severi, Valentina Ambrosini, Robert T. Jensen, Irvin M. Modlin, Matthew H. Kulke, Dik J. Kwekkeboom, Tiny Korse, Richard P. Baum, Ramon Salazar, Marianne Pavel, Andrea Frilling, Helmut R. Maecke, Margot E T Tesselaar, Ignat Drozdov, Kjell Öberg, Jarosław B. Ćwikła, Vikas Prasad, Massimo Falconi, Aldo Scarpa, Dr. Heinz-Horst Deichmann Stiftung, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Oberg, Kjell, Krenning, Eric, Sundin, Ander, Bodei, Lisa, Kidd, Mark, Tesselaar, Margot, Ambrosini, Valentina, Baum, Richard P, Kulke, Matthew, Pavel, Marianne, Cwikla, Jaroslaw, Drozdov, Ignat, Falconi, Massimo, Fazio, Nicola, Frilling, Andrea, Jensen, Robert, Koopmans, Klau, Korse, Tiny, Kwekkeboom, Dik, Maecke, Helmut, Paganelli, Giovanni, Salazar, Ramon, Severi, Stefano, Strosberg, Jonathan, Prasad, Vika, Scarpa, Aldo, Grossman, Ashley, Walenkamp, Annemeik, Cives, Mauro, Virgolini, Irene, Kjaer, Andrea, Modlin, Irvin M, Radiology & Nuclear Medicine, Oberg, K., Krenning, E., Sundin, A., Bodei, L., Kidd, M., Tesselaar, M., Ambrosini, V., Baum, R. P., Kulke, M., Pavel, M., Cwikla, J., Drozdov, I., Falconi, M., Fazio, N., Frilling, A., Jensen, R., Koopmans, K., Korse, T., Kwekkeboom, D., Maecke, H., Paganelli, G., Salazar, R., Severi, S., Strosberg, J., Prasad, V., Scarpa, A., Grossman, A., Walenkamp, A., Cives, M., Virgolini, I., Kjaer, A., and Modlin, I. M.

Subjects
Oncology, carcinoid, Pathology, GA-68-DOTA-TYR(3)-OCTREOTIDE PET, Endocrinology, Diabetes and Metabolism, Computed tomography, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit, CHROMOGRANIN-A, Biomarker, Carcinoid, CT scan, CTC, Delphic consensus, Imaging, MRI, MRNA, Multianalyte, NETest, Neuroendocrine tumor, PET, RECIST, Somatostatin, Internal Medicine, Endocrinology, lcsh:Diseases of the endocrine glands. Clinical endocrinology, Imaging modalities, PROGNOSTIC-FACTORS, 0302 clinical medicine, Medicine, Disease management (health), ENDOCRINE NEOPLASIA TYPE-1, medicine.diagnostic_test, imaging, Diabetes and Metabolism, GUIDELINES UPDATE, 030220 oncology & carcinogenesis, Endokrinologi och diabetes, Biomarker (medicine), biomarker, neuroendocrine tumor, medicine.medical_specialty, TRANSCRIPT ANALYSIS, mRNA, 030209 endocrinology & metabolism, somatostatin, Endocrinology and Diabetes, NO, Delphic consensu, 03 medical and health sciences, POSITRON-EMISSION-TOMOGRAPHY, Breast cancer, multianalyte, Internal medicine, Journal Article, BREAST-CANCER, Gastroenteropancreatic neuroendocrine tumor, Neuroendocrine neoplasia, lcsh:RC648-665, business.industry, Research, CLINICAL UTILITY, Transcript analysis, medicine.disease, MEDIATED RADIONUCLIDE THERAPY, business
Abstract

The complexity of the clinical management of neuroendocrine neoplasia (NEN) is exacerbated by limitations in imaging modalities and a paucity of clinically useful biomarkers. Limitations in currently available imaging modalities reflect difficulties in measuring an intrinsically indolent disease, resolution inadequacies and inter-/intra-facility device variability and that RECIST (Response Evaluation Criteria in Solid Tumors) criteria are not optimal for NEN. Limitations of currently used biomarkers are that they are secretory biomarkers (chromogranin A, serotonin, neuron-specific enolase and pancreastatin); monoanalyte measurements; and lack sensitivity, specificity and predictive capacity. None of them meet the NIH metrics for clinical usage. A multinational, multidisciplinary Delphi consensus meeting of NEN experts (n = 33) assessed current imaging strategies and biomarkers in NEN management. Consensus (>75%) was achieved for 78% of the 142 questions. The panel concluded that morphological imaging has a diagnostic value. However, both imaging and current single-analyte biomarkers exhibit substantial limitations in measuring the disease status and predicting the therapeutic efficacy. RECIST remains suboptimal as a metric. A critical unmet need is the development of a clinico-biological tool to provide enhanced information regarding precise disease status and treatment response. The group considered that circulating RNA was better than current general NEN biomarkers and preliminary clinical data were considered promising. It was resolved that circulating multianalyte mRNA (NETest) had clinical utility in both diagnosis and monitoring disease status and therapeutic efficacy. Overall, it was concluded that a combination of tumor spatial and functional imaging with circulating transcripts (mRNA) would represent the future strategy for real-time monitoring of disease progress and therapeutic efficacy.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results